The UK health and social care sector is under sustained pressure. Rising demand, workforce shortages and an ageing population have created a level of strain that services are struggling to absorb, and the backlog sitting behind it shows little sign of clearing quickly. The BMA has reported that it will take years to work through, and NHS waiting times data shows that in May 2026 the waiting list in England stood at 7,272,291 pathways, representing around 6,152,666 individual patients.
Pressure on that scale changes how services think about where care actually needs to happen. Acute beds are finite, and every day a medically stable patient spends on a ward is a day that bed is unavailable to someone else. That reality is driving a shift towards treating patients closer to home wherever it is clinically appropriate, and antibiotic delivery is one of the clearest examples.
Community antibiotic treatment moves the management of selected acute and chronic infections out of the hospital ward and into outpatient clinics, community settings and patients’ own homes. With the right clinical governance behind it, it eases pressure on acute services while giving suitable patients access to treatment at a time and place that fits around their lives
Does antibiotic treatment always have to take place in hospital?
Patients requiring antimicrobial therapy have traditionally been managed in hospital, particularly where parenteral treatment is needed. For a proportion of those patients, though, a community treatment pathway is a realistic alternative.
Community pathways for antimicrobial delivery, usually referred to as Outpatient Parenteral Antimicrobial Therapy (OPAT), allow patients to receive complex antimicrobial treatment safely outside a traditional hospital ward. Well-run services prevent unnecessary admissions and support earlier, supported discharge for patients who are medically stable but still part-way through a course of treatment. OPAT is generally accepted as safe and clinically effective when it is delivered within a formal service model with appropriate clinical governance, and it has been found to be both preferred by patients and cost-effective compared with inpatient care.
The important word there is “model”. Successful community-based treatment relies on far more than simply giving an infusion outside hospital. It requires:
- Careful patient assessment and selection by a multidisciplinary team.
- The right antimicrobial and route of administration, chosen on clinical grounds.
- Microbiology and antimicrobial input on the agent, dose and duration.
- Reliable, practical delivery technology that works in a home as well as a hospital. The Freedom60 syringe infusion system is one option used to support community infusion pathways, and is cleared for intravenous infusion of certain targeted antibiotics including meropenem, ertapenem, oxacillin and tobramycin.
Get those elements right and community treatment becomes a genuine clinical pathway rather than a workaround for bed pressure.
The benefits of community-based treatment pathways for antimicrobial treatment
The case for community antibiotic treatment works from two directions: what it offers the patient, and what it offers the wider system.
For patients, the appeal is fairly obvious. Treatment can often start sooner and receiving it closer to home means less disruption to work, family and daily routine. Many people recover better in familiar surroundings, and time spent out of hospital also means a lower risk of picking up a hospital-associated infection, which matters particularly over the winter months when respiratory infections are circulating widely.
For the healthcare system, moving appropriate patients into community pathways helps relieve some of the pressure hospitals are carrying and frees acute capacity for emergency and severely unwell patients. For those already admitted, it can support an earlier discharge, getting the patient home sooner and returning the bed to use. There is a financial argument too. Clinical homecare already saves the NHS around £1.6 billion a year, the equivalent of roughly 1.5 million bed days.
Choosing the right treatment pathway
Community antibiotic treatment suits some patients well and is inappropriate for others, and the difference is a clinical judgement rather than a logistical one. Clinical stability is the starting point. Patients should be responding predictably to treatment, with no signs of deterioration and no unresolved diagnostic questions that still need inpatient investigation. The infection matters just as much. Certain bone and joint infections, endocarditis and complicated skin and soft tissue infections are managed successfully in OPAT services, while others need the intensity of inpatient care, particularly where deterioration is a risk or source control has not been achieved.
Route and frequency then shape what is practical. A once-daily agent is easier to deliver at home than one requiring multiple doses, and vascular access, including who will care for the device, should be settled before discharge. The home environment, access to a telephone and transport, and whether the patient or a carer can take part all count as well. Updated UK OPAT recommendations are clear that these decisions belong to a multidisciplinary team rather than to any one individual.
The role of microbiology teams in community antimicrobial treatment
Microbiology and infection teams sit at the centre of any credible community pathway. Their involvement is what separates a clinically governed service from an administrative attempt to move patients out of beds.
They interpret culture and susceptibility results in clinical context, since a result rarely speaks for itself. They determine which antimicrobial is used, at what dose and for how long, and when treatment should stop. And they stay involved after discharge, reviewing response, blood results and line site, with a clear route to change therapy, switch to oral treatment or bring the patient back into hospital.
Stewardship runs through all of it. NICE NG15 sets out how organisations should run antimicrobial stewardship programmes, and those expectations apply as much in the community as on a ward. Antimicrobial choice, dose, duration and route remain clinical
Where does subcutaneous antibiotic therapy fit?
Subcutaneous administration of antimicrobials is an emerging area within OPAT rather than an established default. The interest is understandable for several reasons. Some patients have difficult venous access, some cannot safely maintain a line, and for others, particularly frail or palliative patients, the burden of intravenous access outweighs its benefits. In those situations, the subcutaneous route may be considered where clinically appropriate, case by case and with specialist input.
Drug selection is critical. Only a small number of antimicrobials have been studied by this route, and pharmacokinetics, tolerability and tissue irritation vary between agents. A 2026 observational study of 136 patients receiving subcutaneous ceftriaxone, teicoplanin or ertapenem reported a clinical cure rate of 92.6%, though in a selected population that is supportive evidence rather than proof of equivalence. It is not a replacement for intravenous therapy and should be documented and monitored as carefully as any other route.
Supporting community infusion pathways with Freedom60
Once a pathway has been prescribed, it still has to be delivered, often in a living room rather than a clinical environment. That is where infusion equipment earns its place.
The Freedom60 syringe infusion system is a portable mechanical syringe driver. It runs on a spring mechanism rather than batteries or mains electricity, removing a set of problems that matter more in the community than in hospital: no charging, no power failures and nothing to source when a visit runs late. It delivers at a constant pressure rather than forcing a fixed rate, with flow determined by the administration set, so the system responds to resistance in the line rather than pushing against it. Its size and simplicity suit home pathways, where equipment may be handled by community nurses, carers or trained patients.
Reliable infusion technology does not determine which antibiotic a patient receives or for how long. It supports the safe delivery of a pathway clinical teams have already designed.
Creating a safe community pathway
Services that run well tend to share the same five foundations.
- Clinical assessment against agreed criteria covering stability, infection type, comorbidities and social circumstances, revisited if the picture changes.
- Microbiology oversight, with infection specialists confirming the plan before discharge and staying involved throughout.
- Delivery planning covering vascular access, drug supply and stability, equipment, nursing visits, waste disposal and training.
- Patient education and community support, so patients and carers know how to care for the line, what warning signs matter and who to contact out of hours.
- Monitoring and escalation to an agreed schedule, with a defined, rapid route back into hospital and governance mirroring that expected on a ward.
Reducing avoidable hospital pressure where appropriate
Community antimicrobial pathways relieve pressure in two ways: earlier discharge for patients who are stable but still need parenteral treatment and avoided admissions where a patient can be started on treatment without occupying a bed. Both align with the direction of national policy. NHS England’s virtual ward and hospital at home programmes, the neighbourhood health guidelines for 2025/26 and the DHSC 10 Year Health Plan all point towards care closer to home, supported by properly resourced community teams.
The qualifier matters. This works when the right patients are treated in the right setting, not when community pathways are used to relieve pressure on services that are not equipped to take it.
Amdel Medical supports community-based treatment pathways with the Freedom60
The NHS is moving steadily towards care closer to home, and antimicrobial therapy is one area where that shift is both practical and well evidenced. What makes it work is clinical rigour. Microbiology-led decision-making determines which patients are suitable, which agent is used, at what dose, by which route and for how long, with monitoring that holds up outside hospital walls.
Emerging options such as subcutaneous administration may widen the range of patients treated in the community, but only within those same boundaries. Systems such as Freedom60 support the practical delivery of prescribed infusion therapy outside hospital, where that is clinically appropriate. To learn more about the Freedom60 and how it can support community-based treatment pathways, get in touch with our team today.